Current Medical Use of Rx Stimulants for ADHD Up in Teens From 2005 to 2023
By Lori Solomon HealthDay Reporter
TUESDAY, Aug. 5, 2025 -- Among U.S. adolescents, current medical use of prescription stimulants for attention-deficit/hyperactivity disorder (ADHD) increased between 2005 and 2023, while nonmedical use decreased, according to a research letter published online July 29 in the Journal of the American Medical Association.
Sean Esteban McCabe, Ph.D., from the University of Michigan in Ann Arbor, and colleagues examined trends in medical and nonmedical prescription stimulant use patterns for ADHD among U.S. adolescents. The analysis included data from 259,623 students (eighth, 10th, and 12th grades) participating in the Monitoring the Future study (2005 to 2023).
The researchers found that lifetime medical use of prescription stimulants for ADHD peaked in 2022 at 9.30 percent. There was a linear, nonsignificant trend. The lowest point for lifetime nonmedical use was 4.69 percent in 2023, with a significant decrease over time (adjusted odds ratio [aOR] linear trend, 0.971). For current medical use of prescription stimulants, the peak was in 2022 at 4.46 percent, with modest increases over time (aOR linear trend, 1.016). Among participants with current medical use, 14.5 percent had used prescription stimulants for less than one year, 18.6 percent for one to two years, and 66.9 percent for three years or longer. Over time, current medical and nonmedical co-use decreased (aOR linear trend, 0.980). Participants in 10th and 12th grade had a greater prevalence of nonmedical use of prescription stimulants but also experienced greater declines in nonmedical use over time.
"Despite concerns about increased stimulant prescribing, findings indicate no associated increase in nonmedical prescription stimulant use at this time, although longitudinal research and continued monitoring is necessary," the authors write.
One author disclosed ties to relevant organizations.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
AAP Updates Screening Guidance for Child Mental Health, Behavioral Problems
MONDAY, Aug. 25, 2025 -- In a clinical report issued by the American Academy of Pediatrics and published online Aug. 25 in Pediatrics, updated recommendations are presented for...
Discordance Seen Between Care Goals, Treatment Intent in Advanced Cancer
MONDAY, Aug. 25, 2025 -- More patients with advanced cancer report that their treatment discordantly focuses on longevity over comfort than patients with other illnesses...
Apitegromab Improves Motor Function in Spinal Muscular Atrophy
MONDAY, Aug. 25, 2025 -- For patients with nonambulatory type 2 or type 3 spinal muscular atrophy, apitegromab, a monoclonal antibody that inhibits myostatin activation, improves...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.